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Abstract. Plasma progranulin (PGRN) levels constitute a potentially invaluable biomarker for neurodegenerative diseases
including frontotemporal lobar degeneration (FTLD) and, perhaps, Alzheimer’s disease (AD). We assessed plasma PGRN levels
in 107 AD patients, 36 FTLD patients, and 107 controls. We found that, in female AD patients, there is a positive correlation
between PGRN levels and age. Although no significant differences were found between patients and controls, we observed
higher levels in females compared to males; in AD patients, a positive correlation between PGRN levels and age was observed
in females. In conclusion, our data suggest that PGRN may not be a good biomarker for AD; moreover, gender may influence
the plasma PGRN levels of AD patients.
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INTRODUCTION
The neurobiology of progranulin (PGRN) has sug-
gested that this protein may act as a neuroprotective
agent against hypoxic/anoxic insults in the brain [1]
and in neuroinflammation [2]. Moreover, PGRN has
been found to influence the sexual differentiation of
the brain; thus, in neonatal male mouse, androgen-
dependent upregulation of PGRN expression in the
hypothalamus is associated with its sexual differen-
tiation [3].
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Mutations in the progranulin gene (GRN; MIM
138945) were identified as a causal mechanism under-
lying frontotemporal lobar degeneration (FTLD). Most
pathogenic GRN mutations lead to a frameshift or
premature stop codon resulting in abnormal mRNA
transcripts that undergo nonsense-mediated mRNA
decay resulting in a lack of expression [4, 5].
Furthermore, GRN mutations have been associated
with widely variable clinical phenotypes, including
Alzheimer’s disease (AD) [6–9].
AD is the most common form of primary degenera-
tive dementia. Clinico-pathological studies support the
notion of a long ‘preclinical’ stage of disease; in fact
it is thought that brain pathology, consisting of amy-
loid plaques and neurofibrillary tangles, begins 10–20
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years before significant neuronal cell death and the sub-
sequent appearance of any cognitive and behavioral
symptoms [10]. Thus, fluid and imaging biomarkers
could identify subjects in early symptomatic and even
preclinical stages, possibly when potential treatments
can best preserve cognitive function [11].
Carriers of numerous different types of GRN-null
mutations show significantly reduced plasma PGRN
concentrations due to the loss of one functional copy
of GRN transcript, such that PGRN levels could
distinguish between carriers and non-carriers of the
mutation, with a high sensitivity and specificity of
roughly 100% [12]. This makes PGRN a promis-
ing biomarker to identify causative GRN mutations
in patients with AD as well. However, not much is
known about the possible roles of PGRN in GRN
mutation non-carriers subjects. Recently, some com-
mon variants of GRN were found to be associated with
AD, probably due to their influence on GRN mRNA
expression levels [13]. In particular, the rs5848 poly-
morphism was found to influence serum PGRN levels,
with TT carriers having a lower level of serum PGRN
than CT and CC carriers [14].
In this pilot study, we assessed the possible role
of plasma PGRN as a biomarker in AD, and tested
whether age and gender influence its levels.
METHODS
Patients
Two hundred and fourteen subjects enrolled at the
Memory Clinic, University “Sapienza”, Rome and at
the Alzheimer’s Unit of Ospedale Maggiore Policlin-
ico, Milan, between 2006 and 2011. The study protocol
was approved by the local Institutional Review Boards
and written informed consent was obtained from each
participant. The control group consisted of healthy
volunteers: non-consanguineous family members or
caregivers of AD patients.
Patients were diagnosed according to the DSM-IV
and NINCDS-ADRDA criteria [15]. All participants
underwent neurological examination and standard-
ized neuropsychological evaluation by Mini-Mental
State Examination and standardized neuropsycholog-
ical tests [16, 17].
One hundred and seven subjects were diagnosed
with probable AD (71 women and 36 men; mean age
71.8 ± 7.8 years; duration of disease 3.80 ± 3.02 years)
and the duration of disease was calculated from the
onset of symptoms.
The cohort consisted of 36 patients with a familial
form of AD having two or more first-degree relatives
who had a history of AD-like dementia and 71 with
sporadic AD. Moreover, 40 patients had an early dis-
ease onset (≤65 years), whereas the remainder had a
late onset (>65 years).
The control group consisted of 107 healthy volun-
teers matched for age, gender, and ethnic background
(74 women and 33 men, mean age 69.4 ± 10.3 years).
Blood samples collected into EDTA were centrifuged
at 2,000 rpm for 10 min, and the plasma was collected,
aliquoted, and immediately frozen at −70◦C until anal-
ysis.
Genetic analysis
Genomic DNA was isolated from whole blood
using a Flexigene Kit (Qiagen, Hildren, Gemany) as
described by the manufacturer. To exclude the pres-
ence of causal mutations in the GRN gene, the entire
open reading frame, including the noncoding exon 1
and exon–intron boundaries of exons 2–13 of the GRN
gene (http://www.molgen.ua.ac.be/), was sequenced in
AD patients, using specific primers [18, 19]. For APOE
genotyping, DNA was amplified using specific primers
and then digested with HhaI, as previously described
[20].
Progranulin level evaluation
Plasma PGRN levels were measured using an
ELISA kit (Human Progranulin ELISA Kit, Adipo-
Gen Inc., Seoul, Korea). Samples were diluted
1:100 and processed according to the manufacturer’s
instructions.
Statistical analysis
The Kolmogorov-Smirnov test was applied to test
for a normal distribution of plasma levels of PGRN,
age, and duration of disease. Parametric tests includ-
ing the t-test or Pearson correlation test were used to
compare means in independent samples or correlate
two variables when appropriate. A chi square test was
used for categorical variables. A logistic-regression
model was run to evaluate the relation between gen-
der and plasma levels of PGRN adjusted for age and
conditions (AD versus healthy controls). In the logistic
analysis, the plasma levels of PGRN were considered
in three categories according to the 33rd percentile dis-
tribution: a) low, with values included between 70 and
124.6 ng/ml; b) medium with values between 124.7
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and 192.2; and c) high, with values between 192.3
and 498.6. Data were analyzed using SPSS 20.0 for
Windows (SPSS Inc., Chicago, IL). Differences were
considered to be significant at p < 0.05.
RESULTS
No mutations of the GRN gene were found in AD
patients. Demographic and biochemical features of the
patients and controls are summarized in Table 1.
The Kolmogorov-Smirnov test showed a statisti-
cally significant p value for the departure from normal
distribution of plasma levels of PGRN (p = 0.002), age
(p = 0.001), and duration of disease (p = 0.001). For this
reason, we used parametric tests for further analyses.
No differences in age or gender distribution were
observed between patients and controls (p > 0.05). The
APOE 4 frequency was statistically different in AD
patients with respect to controls (50.4% versus 16.8%;
p = 0.001). In an overall assessment, we found no sig-
nificant differences in plasma PGRN concentration
between patients and healthy controls. However, a sig-
nificant gender difference in plasma PGRN levels was
shown, with higher levels in female (mean value ± SD:
183.91 ± 82.33 ng/ml) compared to male subjects
(mean value ± SD: 152.31 ± 68.63 ng/ml; p = 0.006)
(Table 2). In particular, the difference reached
significance threshold in AD patients (females:
190.33 ± 87.40 ng/ml versus males: 154.80 ± 61.78
ng/ml; p = 0.032), whereas in controls, although
the trend was maintained, the difference was not
significant (females: 177.75 ± 77.26 versus males:
149.59 ± 76.29 ng/ml; p = 0.083). Moreover, we per-
formed a sensitivity analysis excluding four extreme
values of plasma levels of PGRN distribution for AD
and controls. The statistical significance of compar-
isons did not substantially change.
In an exploratory analysis in all subjects performed
on subgroups by age and gender, it appeared that
PGRN levels were positively correlated with age in
females (r = 0.272; p = 0.001), but not in males (Fig. 1a,
b). In the AD group, this correlation was confirmed
(r = 0.252; p = 0.034, Fig. 1d). Similar results were
obtained in controls, in which a positive correla-
tion between age and PGRN levels was evident in
the female group (r = 0.283; p = 0.015) (Fig. 1f). The
logistic regression model showed that females had
a two-fold higher risk of high plasma PGRN lev-
els (OR = 2.216; CI 95% 0.984–4.990; p = 0.055) than
males adjusted for age and conditions (AD versus con-
trols) (Table 2).
Finally, almost significantly different PGRN val-
ues were found between patients with a positive
and negative family history of dementia (familial
AD: 158.88 ± 48.37 ng/ml versus sporadic AD:
188.26 ± 92.27 p = 0.08). Moreover, the correlation
Table 1
Comparison between AD patients and healthy controls and between males and females
AD Healthy controls p
All (numbers) 107 107
Age at evaluation in years, mean ± SD (Range) 70.52 ± 9.26 (47–83) 69.39 ± 10.27 (43–86) 0.367
Gender (male/female) 36/71 33/74 0.660
GRN levels (ng/ml), mean ± SD (Range) 178.37 ± 81.17 (76.48–498.60) 169.06 ± 77.71 (70.35–473.40) 0.392
APOE 4 (%) 50.4 16.8 0.001
Males mean ± SD GRN levels (ng/ml) Females mean ± SD GRN levels (ng/ml)
AD patients (range) 154.80 ± 61.78 (76.48–316.00) 190.32 ± 87.40 (79.60–498.60) 0.032
Healthy controls (range) 149.59 ± 76.29 (70.35–473.40) 177.74 ± 77.26 (82.02–373.40) 0.083
All subjects (range) 152.31 ± 68.63 (70.35–473.40) 183.91 ± 82.3 (79.60–498.60) 0.006
Table 2
A logistic-regression model with relation between gender (females versus males) and plasma levels of PGRN adjusted for age and conditions
(AD versus healthy controls)
B SE Wald df Sig OR 95% CI
Lower Upper
PGRN low 3.771 2 0.152 1.000
PGRN medium 0.384 0.357 1.157 1 0.282 1.469 0.729 2.960
PGRN high 0.796 0.414 3.692 1 0.055 2.216 0.984 4.990
Age −0.013 0.018 0.566 1 0.452 0.987 0.953 1.022
AD versus control −0.399 0.416 0.920 1 0.338 0.671 0.297 1.516
Duration disease 0.084 0.074 1.292 1 0.256 1.088 0.941 1.259
Constant 1.317 1.225 1.156 1 0.282 3.734
B, coefficient B; SE, standard error; Wald, Wald test; df, degrees of freedom; Sig, significance; OR, odds ratio; 95% CI, 95% confidence interval.
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Fig. 1. Age-related increased levels on plasma PGRN are associated with gender. Correlation analysis between age and PGRN in all subjects
(a, b) and in separate groups of AD (c, d) and controls (e, f).
analysis showed a borderline inverse relationship
between plasmatic PGRN levels and duration of dis-
ease (r = −0.166; p = 0.088) with no difference when
the analyses were performed separately for each
gender.
In an ancillary analysis, performed on a small
group of patients affected by FTLD (20 men and 16
women; mean age 71.3 ± 8.1 years; duration of disease
3.61 ± 2.84 years), we found a borderline gender dif-
ference in plasma PGRN levels (152.09 ± 64.15 ng/ml
versus 197.74 ± 101.60 ng/ml; p = 0.11) and no corre-
lation between plasmatic PGRN levels and duration of
disease and age in all patients or separately by gender.
Lastly, all subjects were genotyped for APOE to
determine whether the levels of PGRN were associated
with the 4 allele. We found no differences between the
genotype and allele frequencies of APOE and PGRN
concentration.
DISCUSSION
In this study we investigated the possible differ-
ences in plasma PGRN levels between patients with
AD and healthy controls. Our results showed that there
were no differences between the two groups analyzed,
while a significant difference was observed according
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to gender, in particular in AD subjects with a higher
PGRN level in females compared to males. Finch and
colleagues reported a similar gender difference in the
expression levels of plasma GRN in a group of FTLD
patients [21].
Our data suggest a possible influence of gender on
PGRN expression in some neurodegenerative diseases.
In AD, female gender has been associated with an
increased risk of disease development. In fact, there
is general agreement on the higher prevalence of AD
in women. It is well known that the main risk factor for
AD is increasing age, and women have a well-known
survival advantage over men [22, 23]; moreover,
clear gender differences in the pathological features
of AD and its relationship with behavioral distur-
bances indicate a biological basis for these differences
[24, 25].
The dramatic loss of estrogen at menopause is gener-
ally acknowledged as a risk factor for the development
of AD in women [26–28]. Although there is no consen-
sus on differences in circulating levels of estradiol in
control subjects and women with AD, brain estrogen
have been shown to be lower than normal in female
subjects with AD [29, 30]. In the last decade, a novel
biological aspect of PGRN as a mediator in sexual dif-
ferentiation of the developing brain was demonstrated
such that PGRN may be involved in masculiniza-
tion of the perinatal rat brain. In fact, transcription
of PGRN was upregulated by exogenous estrogen
in the neonatal hypothalamus [31] and, in males, it
is maintained at high levels throughout the critical
period, while in females it gradually decreases and
then declines abruptly after birth [32]. Moreover, in
adult rats PGRN gene expression is upregulated by
estrogen in the hippocampus [33]. These data sug-
gest a role of PGRN in sexual differentiation of the
developing brain and an influence of estrogen on its
expression.
Regarding the PGRN expression in patients with AD
and healthy controls, we found no differences between
these two groups, but we observed an inverse relation-
ship between plasmatic PGRN levels and duration of
disease. Our results do not seem to support a major role
of PGRN in AD as a possible biomarker in plasma
samples. However, it could potentially be used as a
marker of disease progression. Moreover, when the
analyses were performed separately for gender, we
found a weak but not significant difference between
AD and controls in females. Interestingly, the gender-
dependent differences in PGRN expression were more
evident in affected females compared to healthy sub-
jects; this inhomogeneity could be associated with a
different effect of PGRN on disease between women
and men. Gender-dependent differences in AD could
also be very effective in determining drug efficacy in
AD therapy. It is well known that men have a 73%
greater chance of responding to anticholinesterase ther-
apies than women [34].
However, on the basis of the number of male and
female AD patients and the observed mean and stan-
dard deviation of PGRN plasmatic values in the two
groups, we can estimate a power of 69.3% in these
findings.
In conclusion, we observed an association between
the female gender and PGRN levels, as well as a cor-
relation between such levels and age in the female
population, both with and without AD. Further studies
in a larger population would be needed to con-
firm the gender-related involvement of PGRN in the
pathogenesis of AD and in the different forms of
disease, and to better characterize its role in disease
progression.
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